http://pinoybizblogger.tradepub.com/?pt=cat&page=ALL Tue, 30 Jun 2026 08:20:07 -0700 Free trade magazines, white papers, downloads and podcasts for business professionals http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_actp03 http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_actp03 Tue, 30 Jun 2026 07:40:48 -0700 <table><tr><td valign=top><a href="http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_actp03"><img src="http://img.tradepub.com/free/w_actp03/images/w_actp03c.gif" border=0></a></td><td valign=top><p>Pharma field reps need more than product knowledge to succeed&mdash;they need clinical confidence, adaptability, and the ability to handle real HCP conversations under pressure.</p> <p>Download this success guide to learn how AI-simulated roleplay can help commercial learning and sales enablement teams prepare reps for the conversations that matter most.</p> <p>Inside, you&rsquo;ll discover how to:</p> <ul> <li>Create a safe, judgment-free practice environment for reps</li> <li>Give teams on-demand access to realistic roleplay anytime, anywhere</li> <li>Deliver immediate, actionable feedback without waiting for manager review</li> <li>Use realistic HCP avatars that ask clinically relevant questions and respond dynamically</li> <li>Build clinical fluency, product mastery, and objection-handling confidence</li> <li>Make practice more engaging with gamification, performance trends, and personal bests</li> </ul> <p>This guide is built for pharma commercial leaders, sales enablement teams, training teams, and field excellence professionals looking to improve rep readiness, message consistency, and in-field performance.</p> <p>Get the guide to see what effective AI-simulated roleplay for pharma field reps should look like.</p><br><br><a href="http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_actp03">Request Free!</a></td></tr></table> http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_nexu80 http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_nexu80 Tue, 30 Jun 2026 07:40:09 -0700 <table><tr><td valign=top><a href="http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_nexu80"><img src="http://img.tradepub.com/free/w_nexu80/images/w_nexu80c.gif" border=0></a></td><td valign=top><p>Supporting IBM Sterling OMS at scale quietly became a people problem &mdash; monitoring, triage, and reconciliation eating up your best engineers' days. This field report breaks down where the effort actually goes, what's automatable now, and how to shift from reactive firefighting to proactive operations.</p> <p>IBM Sterling OMS is proven, and it scales. But the support model bolted around it &mdash; reactive, shift-based, dependent on a handful of people who know how everything behaves &mdash; hasn't kept pace. The result is an operation that's busy, expensive, and quietly fragile, where skilled engineers spend their days watching dashboards and chasing stuck orders instead of moving the business forward.<br /> <br /> Drawing on task-execution data from a live production Sterling environment, this report shows where that effort really goes and what a more modern operating model looks like.<br /> &nbsp;</p> <p><strong>What's inside:</strong></p> <ul> <li><strong>The 75% breakdown&nbsp;</strong>&mdash; where OMS support effort actually goes, activity by activity, and why the work that improves your operation always gets the leftovers</li> <li><strong>Why &quot;just add people&quot; doesn't work</strong>&nbsp;&mdash; the talent, knowledge-transfer, and peak-scaling math that caps the reactive model</li> <li><strong>What's genuinely automatable now</strong> (and what isn't) &mdash; an honest, three-tier view of where AI helps and where human judgment still earns its keep</li> <li><strong>The proactive operating model&nbsp;</strong>&mdash; continuous monitoring, anomaly detection before escalation, and what it takes to get there without betting the operation</li> <li><strong>How to start</strong>&nbsp;&mdash; a phased, assessment-led path that delivers value without putting your environment at risk</li> </ul><br><br><a href="http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_nexu80">Request Free!</a></td></tr></table> http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_kind04 http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_kind04 Tue, 30 Jun 2026 07:31:48 -0700 <table><tr><td valign=top><a href="http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_kind04"><img src="http://img.tradepub.com/free/w_kind04/images/w_kind04c.gif" border=0></a></td><td valign=top><p>Every sterile injectable program has a different journey to reach its commercial destination. The molecule, stage of development, delivery system and operational concerns all influence this path.</p> <p>Kindeva&rsquo;s interactive guide helps you identify the priorities that matter most to your program and explore how Bridgeton brings the infrastructure, aseptic controls and integrated support needed to guide sterile fill finish programs from critical decision points to confident execution.</p> <p>Follow your custom pathway to learn how Bridgeton supports:</p> <ul> <li>Flexible clinical manufacturing with a clear path to commercial scale</li> <li>Validation readiness through isolator-based aseptic processing, digital batch oversight and integrated analytics</li> <li>High-throughput commercial supply with annual capacity exceeding 150 million units</li> <li>Streamlined tech transfer through fill finish, assembly, packaging and quality oversight</li> <li>Vial, prefilled syringe and cartridge fill finish options</li> </ul> <p>Start mapping your priorities and see how Kindeva can help provide the structure to reach your next sterile manufacturing milestone.</p><br><br><a href="http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_kind04">Request Free!</a></td></tr></table> http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_schn40 http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_schn40 Tue, 30 Jun 2026 07:31:28 -0700 <table><tr><td valign=top><a href="http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_schn40"><img src="http://img.tradepub.com/free/w_schn40/images/w_schn40c.gif" border=0></a></td><td valign=top><p>The real-world landscape of distributed tech infrastructure in busy, budget-constrained K&ndash;12 environments is this: housing servers, networking gear and UPS equipment in former janitor closets, basement utility rooms and even kitchen spaces. Humidity, dust control and power-related downtime events are widespread problems. This facility design issue is compounding power infrastructure maintenance challenges.</p> <p>This report analyzes survey responses from 152 IT professionals in K&ndash;12 districts to understand how they manage power infrastructure across their buildings. Highlights include:</p> <ul> <li>What they face and why, even though they think they are using the right management tools, there's room for improvement.</li> <li>A data-driven guide to elevating power management in educational environments that are facing significant changes as they integrate AI into their IT infrastructures.</li> <li>Three practical steps resource-constrained districts can take towards a more reliable IT infrastructure.</li> </ul><br><br><a href="http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_schn40">Request Free!</a></td></tr></table> http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_allq09 http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_allq09 Tue, 30 Jun 2026 07:31:08 -0700 <table><tr><td valign=top><a href="http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_allq09"><img src="http://img.tradepub.com/free/w_allq09/images/w_allq09c.gif" border=0></a></td><td valign=top><p>Life sciences sales has fundamentally changed</p> <p>Today&rsquo;s buyers&mdash;HCPs, providers, and stakeholders are more independent, more informed, and less tolerant of outdated sales approaches.</p> <p>In fact, <strong>61% prefer a rep-free experience</strong>, and most will disengage if the outreach isn&rsquo;t relevant.</p> <p>That creates a real challenge for sales and enablement teams.&nbsp; But leading life sciences organizations are adapting and winning.</p> <p>Our new <strong>Sales Success Playbook</strong> for Life Sciences breaks down exactly how. Inside you&rsquo;ll learn how to:&nbsp;</p> <ul> <li>Build <strong>always-on digital buying experiences</strong> that keep deals moving without the rep</li> <li>Replace static PDFs with <strong>modular, high-performing content</strong> buyers actually engage with</li> <li>Use <strong>AI and video-based coaching</strong> to improve rep performance at scale</li> <li>Centralize content, training, and coaching into a <strong>single enablement platform</strong></li> </ul><br><br><a href="http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_allq09">Request Free!</a></td></tr></table> http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_eurp36 http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_eurp36 Tue, 30 Jun 2026 07:30:48 -0700 <table><tr><td valign=top><a href="http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_eurp36"><img src="http://img.tradepub.com/free/w_eurp36/images/w_eurp36c.gif" border=0></a></td><td valign=top><p>Clinical trials are more complex than ever, and the central laboratory sits at the heart of that complexity. This white paper examines the operational and scientific pressures facing today&rsquo;s central labs and how the right partner can make the difference between a study that runs smoothly and one that does not.</p> <p>Drawing on industry data and insights from Eurofins Central Laboratory Director of Scientific Affairs, the paper covers:</p> <ul> <li>Why rising trial complexity is reshaping what sponsors need from a central lab partner</li> <li>Why specimen integrity and global logistics require the same scientific rigor as the testing itself</li> <li>The challenge of harmonizing data across multiregional studies and what it takes to solve it</li> <li>How central laboratories are evolving from testing functions to strategic scientific partners</li> </ul> <p>Whether you are planning a Phase 1 study or managing a global Phase 3 program, this paper offers a grounded perspective on what central laboratory excellence looks like in practice.</p><br><br><a href="http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_eurp36">Request Free!</a></td></tr></table> http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_novp31 http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_novp31 Tue, 30 Jun 2026 07:30:12 -0700 <table><tr><td valign=top><a href="http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_novp31"><img src="http://img.tradepub.com/free/w_novp31/images/w_novp31c.gif" border=0></a></td><td valign=top><p>Live Biotherapeutics (LBPs) are no longer just a scientific curiosity, they are becoming one of the most promising frontiers in modern medicine.</p> <p>By harnessing live microorganisms to restore or modulate human health, LBPs are opening new pathways for treating chronic and complex diseases with precision and minimal toxicity. From gastrointestinal and metabolic disorders to neurodegeneration and oncology, LBPs have the potential to fundamentally reshape how we approach drug development.</p> <p>As interest in LBPs accelerates, Novotech&rsquo;s white paper outlines the opportunities and early-stage challenges shaping this rapidly advancing therapeutic class.</p> <p>The FDA&rsquo;s approval of Rebyota&trade; and Vowst&trade; has validated the category, but most programs remain in early development. According to Novotech&rsquo;s analysis:</p> <ul> <li>More than 90 industry-sponsored trials have launched since 2020, but 32% have been withdrawn or suspended due to regulatory, manufacturing, or trial design complexity</li> <li>Preclinical and early-phase LBP programs are increasingly targeting Alzheimer&rsquo;s, IBD, diabetes, and NASH</li> <li>North America and Europe lead in regulatory and CDMO investment, but Asia-Pacific is gaining momentum</li> <li>The global market for microbiome CDMO services is projected to grow at a CAGR of 38% through 2030</li> </ul> <p>With investment growing and competition intensifying, the next wave of success will require biotech sponsors to master clinical feasibility, regulatory navigation, and smart trial design from the earliest stages.</p> <p><strong>Download the white paper </strong></p><br><br><a href="http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_novp31">Request Free!</a></td></tr></table> http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_omnj13 http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_omnj13 Tue, 30 Jun 2026 07:21:33 -0700 <table><tr><td valign=top><a href="http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_omnj13"><img src="http://img.tradepub.com/free/w_omnj13/images/w_omnj13c.gif" border=0></a></td><td valign=top><p>Early-onset cancers are rising among adults 18&ndash;49, challenging long-held assumptions about who cancer affects and how patients need to be reached, supported and understood.</p> <p><em>The New Age of Cancer</em> explores what this shift means for the oncology ecosystem, and why pharma and health marketers may need to rethink the way they engage a generation of patients whose lives, expectations and care journeys look very different from the ones today&rsquo;s models were built around.</p> <p><strong>Download the report for a closer look at:</strong></p> <ul> <li>The forces reshaping the cancer experience</li> <li>The gaps younger patients are navigating</li> <li>The role of data, AI and digital engagement</li> <li>The opportunity for pharma to show up differently</li> </ul><br><br><a href="http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_omnj13">Request Free!</a></td></tr></table> http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_meeg13 http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_meeg13 Tue, 30 Jun 2026 07:21:13 -0700 <table><tr><td valign=top><a href="http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_meeg13"><img src="http://img.tradepub.com/free/w_meeg13/images/w_meeg13c.gif" border=0></a></td><td valign=top><p>Healthcare organizations face mounting pressure to modernize provider operations &mdash; but credentialing isn't a generic automation problem. Governed by NCQA, CMS, and payer-specific requirements, these workflows demand more than speed. They require accuracy, oversight, and audit-ready accountability.</p> <p>This guide outlines five principles for evaluating AI in credentialing: purpose-built design for regulated workflows, human oversight that keeps organizations accountable, security and governance that protect sensitive provider data, audit-ready accuracy with traceable outputs, and measurable operational outcomes that directly improve time-to-revenue.</p> <p>Because in credentialing, the right AI doesn't just move faster &mdash; it moves with confidence.</p><br><br><a href="http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_meeg13">Request Free!</a></td></tr></table> http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_bioq17 http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_bioq17 Tue, 30 Jun 2026 07:20:59 -0700 <table><tr><td valign=top><a href="http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_bioq17"><img src="http://img.tradepub.com/free/w_bioq17/images/w_bioq17c.gif" border=0></a></td><td valign=top><p>Bio-Expo Live: Bioprocess Quality, Data, &amp; Analytical Solutions brings together industry experts and leading suppliers to showcase the latest technologies designed to support biopharmaceutical development and manufacturing.</p> <p>Why watch?</p> <ul> <li>Explore the newest quality, data, and analytical solutions helping organizations improve process understanding, compliance, and operational efficiency.</li> <li>Discover innovative equipment and software designed to address key challenges across biopharmaceutical development and manufacturing.</li> <li>Engage directly with solution providers through live Q&amp;A sessions and gain insights tailored to your organization's needs.</li> <li>Learn from concise, expert-led presentations that deliver practical information and actionable takeaways.</li> <li>Evaluate emerging technologies and potential partners in a convenient, interactive virtual environment.</li> </ul> <p>If you're part of a biopharma company or contract manufacturing organization seeking quality, data, or analytical solutions to strengthen your operations, this event offers an efficient way to discover new technologies, connect with suppliers, and stay informed on the latest industry advancements.</p><br><br><a href="http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_bioq17">Request Free!</a></td></tr></table> http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_bioq16 http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_bioq16 Tue, 30 Jun 2026 07:20:39 -0700 <table><tr><td valign=top><a href="http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_bioq16"><img src="http://img.tradepub.com/free/w_bioq16/images/w_bioq16c.gif" border=0></a></td><td valign=top><p>Bio-Expo Live: Downstream Bioprocessing brings together industry suppliers and biopharma professionals for an interactive virtual event focused on innovative solutions for purification, recovery, and downstream process optimization.</p> <p>Why watch?</p> <ul> <li>Discover the latest downstream bioprocessing technologies supporting therapeutic modalities from ADCs to vaccines.</li> <li>Explore innovative equipment and solutions designed to address common purification and manufacturing challenges.</li> <li>Connect directly with solution providers through live Q&amp;A sessions and gain insights relevant to your specific processes.</li> <li>Learn from concise, expert-led presentations that deliver practical information in an efficient format.</li> <li>Evaluate emerging technologies and potential partners from the convenience of your computer.</li> </ul> <p>If you're part of a biopharma company or contract manufacturing organization looking for new ways to enhance downstream operations, this event offers a valuable opportunity to explore solutions, ask questions, and stay ahead of industry trends.</p><br><br><a href="http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_bioq16">Request Free!</a></td></tr></table> http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_bioq15 http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_bioq15 Tue, 30 Jun 2026 07:20:19 -0700 <table><tr><td valign=top><a href="http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_bioq15"><img src="http://img.tradepub.com/free/w_bioq15/images/w_bioq15c.gif" border=0></a></td><td valign=top><p>Bio-Expo Live: Upstream Bioprocessing brings together leading suppliers and biopharma professionals for a focused virtual event showcasing innovative equipment and solutions designed to address today's manufacturing challenges.</p> <p>Why watch?</p> <ul> <li>Discover the latest upstream bioprocessing technologies supporting therapeutic areas ranging from ADCs to vaccines.</li> <li>Explore innovative products and solutions designed to improve efficiency and overcome manufacturing bottlenecks.</li> <li>Engage directly with suppliers through live Q&amp;A sessions and get answers tailored to your specific needs.</li> <li>Gain valuable insights through concise, expert-led presentations without leaving your desk.</li> <li>Evaluate potential solutions and partners in a convenient, interactive online environment.</li> </ul> <p>If you're part of a biopharma company or contract manufacturing organization seeking practical solutions for upstream manufacturing challenges, this event offers a valuable opportunity to connect, learn, and identify technologies that can support your process development goals.</p><br><br><a href="http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_bioq15">Request Free!</a></td></tr></table> http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_adrf02 http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_adrf02 Tue, 30 Jun 2026 05:30:25 -0700 <table><tr><td valign=top><a href="http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_adrf02"><img src="http://img.tradepub.com/free/w_adrf02/images/w_adrf02c.gif" border=0></a></td><td valign=top><p>The physical branch is an often-overlooked opportunity for banks to connect with customers and build trust &mdash; yet many branches fail to meet customer expectations. A branch refresh is a low-risk, high-return solution.</p> <p>In this playbook, discover why a branch refresh is crucial to driving business and explore our step-by-step guide to get started, including how to overcome both expected and unexpected pain points.&nbsp;</p> <p>Read this playbook to learn more about:</p> <ul> <li>The power and potential of branch refreshes</li> <li>The difference between refresh and renovate</li> <li>Building your refresh on data</li> <li>The red flags indicating you need a refresh</li> </ul><br><br><a href="http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_adrf02">Request Free!</a></td></tr></table> http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_wile899 http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_wile899 Tue, 30 Jun 2026 00:01:10 -0700 <table><tr><td valign=top><a href="http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_wile899"><img src="http://img.tradepub.com/free/w_wile899/images/w_wile899c.gif" border=0></a></td><td valign=top><p><em>Structured Empowerment: How to Achieve Growth While Promoting Agility</em> by Harvard Business School professor Tatiana Sandino is a groundbreaking guide that addresses the most critical challenge startups face: how to scale effectively without stifling the innovation and spirit that fuel them. This book introduces the concept of &quot;structured empowerment,&quot; a method that allows companies to grow by expertly balancing flexibility with structure.</p> <p>In the book, you&rsquo;ll:</p> <ul> <li>Learn how to empower employees within a structured framework, enabling them to make decisions that propel growth</li> <li>Discover the optimal timing for formalizing management structures without hampering your company&rsquo;s agility</li> <li>Gain insights from real-world examples of companies that have succeeded and failed, illustrating the principles of effective growth management</li> </ul> <p>Perfect for business leaders, managers, and entrepreneurs, <em>Structured Empowerment </em>offers a new perspective on managing fast-paced growth. If you're seeking to maintain the delicate balance between agility and structure as your company scales, this book is your must-have roadmap. Dive into Sandino's expert analysis and practical advice to keep your startup on the path to success. Buy your copy today and start empowering your team for growth.</p> <p>Expires 7/14/2026</p><br><br><a href="http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_wile899">Request Free!</a></td></tr></table> http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_wile898 http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_wile898 Tue, 30 Jun 2026 00:01:05 -0700 <table><tr><td valign=top><a href="http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_wile898"><img src="http://img.tradepub.com/free/w_wile898/images/w_wile898c.gif" border=0></a></td><td valign=top><p>In <em>Robot-Proof: When Machines Have All the Answers, Build Better People</em>, Dr. Vivienne Ming, &ldquo;a force in AI unlike any we have seen before&rdquo; (Mark Minevich, Forbes), helps readers grasp the ugly and the amazing of how individuals, companies, and societies will respond to the changes that are already taking hold due to the advent of AI. Rather than a wonky textbook on machine learning or a utopian/dystopian (take your pick) screed, Robot-Proof is a book about people, exploring what it means to be human in an increasingly automated world.</p> <p>This book presents, then answers, pressing questions that readers may or may not have thought to themselves, such as:</p> <ul> <li>What predicts long-term life outcomes across millions of little kids?</li> <li>What drives career success in both hyper-networked salespeople and hyper-nerdy programmers?</li> <li>Why is the Informational-Exploration Paradox the most terrifying phenomenon you&rsquo;ve never heard of?</li> <li>What predicts the smartest team and how will AI change it?</li> <li>Why are <em>ill-posed problems</em> the future work, education, and a robot-proof humanity?</li> </ul> <p>With poignant insight and delicate care to keep us grounded in the human perspective, <em>Robot-Proof</em> is an entertaining and thought-provoking read for all individuals seeking to understand the next steps in a new and completely unprecedented world.</p> <p>Expires 7/14/2026</p><br><br><a href="http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_wile898">Request Free!</a></td></tr></table> http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_heas32 http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_heas32 Mon, 29 Jun 2026 20:30:19 -0700 <table><tr><td valign=top><a href="http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_heas32"><img src="http://img.tradepub.com/free/w_heas32/images/w_heas32c.gif" border=0></a></td><td valign=top><p>Healthcare marketers face a critical challenge: even clinically precise outreach often fails to drive patient action due to low engagement and complex decision-making.</p> <p>This eBook introduces a practical, consumer science-driven framework to close the gap between outreach and follow-through by aligning communication with how patients actually decide.</p> <p>What you&rsquo;ll learn:</p> <ul> <li><strong>Why engagement stalls:</strong> Patient action is shaped by motivation, barriers, and readiness&mdash;not just awareness.</li> <li><strong>The evolution of personalization:</strong> Moving beyond demographics and clinical data to behavioral and psychographic insights.</li> <li><strong>Five key patient segments:</strong> Actionable psychographic profiles (e.g., Self Achievers, Willful Endurers) that predict decision-making patterns with high accuracy.</li> <li><strong>How to optimize campaigns:</strong> Tailor message framing, timing, and channel strategy to increase relevance and reduce friction.</li> <li><strong>Real-world results:</strong> Case study showing measurable gains in engagement, appointments, and revenue through personalization.</li> <li><strong>Practical implementation steps:</strong> From campaign selection to audience targeting, sequencing, and scaling across teams.</li> </ul><br><br><a href="http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_heas32">Request Free!</a></td></tr></table> http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_staq52 http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_staq52 Mon, 29 Jun 2026 20:20:23 -0700 <table><tr><td valign=top><a href="http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_staq52"><img src="http://img.tradepub.com/free/w_staq52/images/w_staq52c.gif" border=0></a></td><td valign=top><p>The increasing complexity and pace of drug development have revealed a critical gap in the genomic toolkit. In preclinical and translational research settings, teams must evaluate safety, efficacy, and mechanism of action across large multivariable studies, often within tight timelines and with limited biological material. Yet the tools traditionally used for gene expression analysis are increasingly misaligned with these demands, delaying data‑driven internal research go/no‑go decisions and slowing program progress.</p> <p>Researchers need a technology that fills the gap between the low‑throughput verification of conventional plate‑based quantitative PCR (qPCR) and the high‑cost, discovery‑oriented scale of next‑generation sequencing.</p> <p>This white paper explores the limitations of traditional technologies and presents case studies demonstrating the effectiveness of an alternative research approach, covering topics such as:</p> <ul> <li>Why modern drug development studies demand a new research approach</li> <li>How microfluidic qPCR technology addresses these demands</li> <li>Using microfluidic qPCR in research‑stage pharmacodynamic gene expression studies</li> <li>Enabling research biomarker exploration and target validation</li> <li>Profiling gene expression to study immunosuppression‑related pathways in research models</li> </ul> <p>&nbsp;</p> <p><em><strong>For Research Use Only. Not for use in diagnostic procedures.</strong></em></p> <p><em>All product and company names are trademarks&trade; or registered&reg; trademarks of their respective holders. Use of them does not imply any affiliation with or endorsement by them. Third party trademarks do not indicate an endorsement of any Standard BioTools products or services.</em></p><br><br><a href="http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_staq52">Request Free!</a></td></tr></table> http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_eurp35 http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_eurp35 Mon, 29 Jun 2026 20:01:07 -0700 <table><tr><td valign=top><a href="http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_eurp35"><img src="http://img.tradepub.com/free/w_eurp35/images/w_eurp35c.gif" border=0></a></td><td valign=top><p>Bringing an API from early development to commercial manufacturing is increasingly complex, requiring deeper process understanding, stronger control and alignment with evolving regulatory expectations. This whitepaper explores how multivariate process analysis can transform drug substance development by moving beyond one-variable-at-a-time approaches to a more data-rich, risk-based framework.</p> <p>Through practical guidance and real-world case studies, the paper shows how multivariate tools, grounded in Design of Experiments and Quality by Design, help teams map process parameters, identify critical variables and define robust operating ranges.</p> <p>Key takeaways include:</p> <ul> <li>Faster, more informed decision-making through evaluation of multiple process variables at once</li> <li>Improved process understanding and clearer identification of critical parameters and interactions</li> <li>Effective de-risking through early data generation and establishment of defined operational ranges</li> <li>Greater scalability from early-phase development through commercial manufacturing</li> <li>Stronger alignment with regulatory expectations for risk-based, knowledge-driven development</li> </ul> <p>With step-by-step methodologies and case studies, this resource highlights how even complex or time-constrained programs can benefit from accessible multivariate strategies, offering a compelling path to modernize API development and unlock deeper process insight.</p><br><br><a href="http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_eurp35">Request Free!</a></td></tr></table> http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_neog27 http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_neog27 Mon, 29 Jun 2026 19:50:20 -0700 <table><tr><td valign=top><a href="http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_neog27"><img src="http://img.tradepub.com/free/w_neog27/images/w_neog27c.gif" border=0></a></td><td valign=top><p>Precision oncology has advanced rapidly, but real-world outcomes often fall short of expectations. This white paper explores the disconnect between controlled trial data and how cancer is actually diagnosed and treated in practice&mdash;where variability in testing, treatment sequencing, and patient populations can significantly impact results.</p> <p>By integrating multimodal real-world data&mdash;including molecular, clinical, and longitudinal insights&mdash;teams can generate a more complete and representative view of the patient journey. This approach supports better decision-making across development, evidence generation, and access, reducing uncertainty and aligning strategies with real-world oncology care.</p> <p>Access now to learn about:</p> <ul> <li>Why trial data alone isn&rsquo;t enough</li> <li>Reasons real-world variability matters&nbsp;</li> <li>How multimodal data adds critical context</li> <li>Strategies for<strong>&nbsp;</strong>improving&nbsp;study design, feasibility, and overall strategy across the lifecycle</li> <li>The expanding use of real-world evidence in development and access decisions</li> </ul><br><br><a href="http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_neog27">Request Free!</a></td></tr></table> http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_fujj83 http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_fujj83 Mon, 29 Jun 2026 19:50:08 -0700 <table><tr><td valign=top><a href="http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_fujj83"><img src="http://img.tradepub.com/free/w_fujj83/images/w_fujj83c.gif" border=0></a></td><td valign=top><p>Purifying complex biologics from microbial systems is often a bottleneck&mdash;especially without a suitable affinity resin. ShunzymeX introduces a simple, standardized path: universal affinity capture paired with scarless tag removal to preserve native function. The result is faster, more reproducible workflows that scale from development to cGMP. Read on to see how this platform can shorten timelines, cut complexity, and open new options for challenging targets.</p><br><br><a href="http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_fujj83">Request Free!</a></td></tr></table> http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_enze09 http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_enze09 Mon, 29 Jun 2026 19:40:09 -0700 <table><tr><td valign=top><a href="http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_enze09"><img src="http://img.tradepub.com/free/w_enze09/images/w_enze09c.gif" border=0></a></td><td valign=top><p>The rapid expansion of monoclonal antibody (mAb) therapeutics has intensified pressure on biopharmaceutical developers to improve productivity, cost efficiency, and supply reliability while&nbsp;maintaining&nbsp;stringent quality standards. Conventional batch-based manufacturing models continue to present challenges related to scale-dependent capital investment, facility&nbsp;utilization, process variability, and operational flexibility. Increasingly, continuous manufacturing approaches are being explored&nbsp;as a way to&nbsp;integrate upstream and downstream unit operations into more coordinated production workflows supported by real-time monitoring and advanced process control.&nbsp;</p> <p>This&nbsp;whitepaper provides a comprehensive technical, economic, and regulatory framework for implementing continuous manufacturing strategies in&nbsp;mAb&nbsp;production. It examines practical considerations associated with process integration, operational scalability, lifecycle management, and regulatory readiness, while outlining approaches organizations can use to evaluate adoption within existing manufacturing environments.&nbsp;</p> <p>Access now to explore:&nbsp;</p> <ul> <li>Process architecture, robustness, and control considerations&nbsp;</li> <li>Quantitative factors influencing cost of goods, facility footprint, and scalability&nbsp;</li> <li>Practical considerations for technology adoption and lifecycle management&nbsp;</li> <li>Current regulatory perspectives on continuous biomanufacturing&nbsp;</li> <li>Operational and organizational considerations for transitioning from batch-based to continuous production models&nbsp;</li> </ul> <p>Through an evidence-based analysis informed by commercial manufacturing experience,&nbsp;you&rsquo;ll&nbsp;discover&nbsp;how continuous manufacturing approaches may support more scalable, compliant, and economically sustainable biologics production over the long term.&nbsp;Download today!&nbsp;</p><br><br><a href="http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_enze09">Request Free!</a></td></tr></table> http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_quet70 http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_quet70 Mon, 29 Jun 2026 19:20:21 -0700 <table><tr><td valign=top><a href="http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_quet70"><img src="http://img.tradepub.com/free/w_quet70/images/w_quet70c.gif" border=0></a></td><td valign=top><p>Bringing a therapy to market requires a continuous series of strategic decisions across discovery, development, commercialization, and post-market evaluation. As organizations navigate growing complexity across the medicine lifecycle, the quality, relevance, and timeliness of data have become increasingly important to decision-making.&nbsp;</p> <p>Among the expanding range of real-world data sources available today, de-identified laboratory data is playing a growing role in helping organizations better understand patient populations, disease progression, treatment response, and healthcare utilization. While electronic health records, billing claims, and prescription data each contribute important perspectives, laboratory data offers an additional layer of clinical insight grounded in objective biological measurements and near-real-time testing information.&nbsp;</p> <p>Access this whitepaper to explore how timely, precise lab data can support decision-making from discovery through post-market evaluation. You&rsquo;ll learn about:&nbsp;</p> <ul> <li>Why lab data can provide deeper visibility into the patient journey&nbsp;</li> <li>How lab data may strengthen clinical trial planning and execution&nbsp;</li> <li>The growing role of lab data across commercial and health economics strategies&nbsp;</li> <li>Why laboratory data is becoming increasingly relevant in the AI era&nbsp;</li> </ul><br><br><a href="http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_quet70">Request Free!</a></td></tr></table> http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_asym04 http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_asym04 Mon, 29 Jun 2026 19:20:09 -0700 <table><tr><td valign=top><a href="http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_asym04"><img src="http://img.tradepub.com/free/w_asym04/images/w_asym04c.gif" border=0></a></td><td valign=top><p>As TIDES programs advance more rapidly toward late-stage development and commercialization, manufacturing readiness is becoming a critical factor in long-term success. Increasing complexity, evolving supply chain pressures, and rising expectations around scalability and sustainability are reshaping how drug developers approach peptide and oligonucleotide manufacturing.&nbsp;</p> <p>Access this whitepaper&nbsp;to&nbsp;explore a strategic framework for integrated TIDES manufacturing built around five key priorities: Scale, Speed, Supply Security, Sustainability, and Strategic Readiness.&nbsp;You&rsquo;ll&nbsp;learn how integrated manufacturing strategies can help:&nbsp;</p> <ul> <li>Scale peptide and oligonucleotide programs with greater confidence&nbsp;&nbsp;</li> <li>Strengthen raw material sourcing and supply continuity&nbsp;&nbsp;</li> <li>Accelerate CMC execution from development through commercialization&nbsp;&nbsp;</li> <li>Apply advanced technologies to increasingly complex TIDES modalities&nbsp;&nbsp;</li> <li>Prepare for evolving regulatory, sustainability, and market expectations&nbsp;&nbsp;</li> </ul> <p>Download today to&nbsp;examine the capabilities, operational considerations, and partnership models increasingly needed to support the next generation of TIDES development and commercial supply.&nbsp;</p><br><br><a href="http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_asym04">Request Free!</a></td></tr></table> http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_wolt194 http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_wolt194 Mon, 29 Jun 2026 19:10:09 -0700 <table><tr><td valign=top><a href="http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_wolt194"><img src="http://img.tradepub.com/free/w_wolt194/images/w_wolt194c.gif" border=0></a></td><td valign=top><p>Building a connected healthcare ecosystem requires more than integrating technology solutions and sharing care plans. It also needs to be a strategic framework informed by evidence-based decision-making support and interoperability, and driven by responsible use of artificial intelligence.</p> <p>For digital health tech vendors scaling AI-enabled clinical decision support, this means leveraging rigorously reviewed clinical content paired with robust medication intelligence that&rsquo;s available within an explainable workflow. Building upon the clinical data sources that hospitals, health systems, and other ecosystem partners already trust &ndash; leveraging standardized instructions for how AI tools should access and apply curated data to find answers &ndash; will enable digital health companies to embed clinical knowledge into modern AI workflows.</p> <p>Explore this resource and learn:</p> <ul> <li>Why medication intelligence is more than drug data, and how it can improve clinical decision-making</li> <li>Why effective AI-driven solutions need clinical knowledge and workflow orchestration, not just guardrails</li> <li>Why transparent model context protocols (MCPs) are a must for building direct connections to trusted clinical content</li> </ul><br><br><a href="http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_wolt194">Request Free!</a></td></tr></table> http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_catc134 http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_catc134 Mon, 29 Jun 2026 18:40:08 -0700 <table><tr><td valign=top><a href="http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_catc134"><img src="http://img.tradepub.com/free/w_catc134/images/w_catc134c.gif" border=0></a></td><td valign=top><p>AAV manufacturing via transient transfection continues to face a yield ceiling that limits scalability and drives&nbsp;high cost&nbsp;of goods,&nbsp;especially for&nbsp;high-dose systemic programs. As pipelines expand, improving productivity without introducing&nbsp;additional&nbsp;complexity has become a critical focus for development and manufacturing teams.&nbsp;</p> <p>Emerging approaches to&nbsp;optimizing&nbsp;production biology can translate directly into fewer batches and/or reduced&nbsp;scale&nbsp;to meet the same demand. These strategies help reduce footprint, consumables, and QC burden while expanding effective capacity.&nbsp;&nbsp;</p> <p><strong>Access this whitepaper to learn how:&nbsp;</strong></p> <ul> <li>How advances in Rep/Cap design can improve production efficiency without requiring changes to the therapeutic payload, ITRs, or capsid amino acid sequence&nbsp;</li> <li>What&rsquo;s&nbsp;driving higher titers across multiple serotypes (AAV5, AAV6, AAV8, AAV9, AAVrh10), and how to evaluate impact while&nbsp;maintaining&nbsp;comparability across key quality attributes&nbsp;</li> <li>How improving yields without vector redesign may offer a more scalable, lower regulatory-risk pathway to accelerate development timelines and&nbsp;optimize&nbsp;manufacturing economics&nbsp;</li> <li>And more&nbsp;</li> </ul><br><br><a href="http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_catc134">Request Free!</a></td></tr></table> http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_watf08 http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_watf08 Mon, 29 Jun 2026 18:30:10 -0700 <table><tr><td valign=top><a href="http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_watf08"><img src="http://img.tradepub.com/free/w_watf08/images/w_watf08c.gif" border=0></a></td><td valign=top><p>CAR T cell therapies have reshaped immuno‑oncology, yet functional heterogeneity driven by CAR morphology and spatial organization remains challenging to assess at scale. Growing evidence shows that how CARs are distributed on the T cell surface directly influences signaling strength, cytotoxic activity, and persistence&mdash;but these features are difficult to capture with conventional flow cytometry alone.</p> <p>This application note demonstrates how the BD FACSDiscover Platform, integrating spectral flow cytometry with BD CellView Image Technology, enables high‑throughput and real-time analysis of CAR distribution alongside key phenotypic and functional markers. By leveraging fluorescence imaging parameters, researchers can move beyond population‑average measurements also sort functionally relevant CAR spatial phenotypes for downstream studies.&nbsp;</p><br><br><a href="http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_watf08">Request Free!</a></td></tr></table> http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_rqma01 http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_rqma01 Mon, 29 Jun 2026 18:20:18 -0700 <table><tr><td valign=top><a href="http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_rqma01"><img src="http://img.tradepub.com/free/w_rqma01/images/w_rqma01c.gif" border=0></a></td><td valign=top><p>Smart cardiac implants are among the most chemically complex devices on the market, and the FDA has adjusted its expectations accordingly.&nbsp;</p> <p>Multi-material construction, embedded sensors, continuous energy delivery, and long-term implantation create a chemically dynamic environment where materials interact, interfaces evolve, and degradation pathways emerge over time.</p> <p>The FDA now requires deeper identification, tighter quantification, and far more explicit documentation of uncertainty than before. Programs that treat chemical characterization as a late-stage requirement face consequences: deficiency letters, additional testing requests, shifting timelines, and rising costs.&nbsp;</p> <p>Those that integrate advanced testing early have the potential to benefit from compressed timelines, lower development costs, and a smoother regulatory process.&nbsp;</p> <p>Download the white paper to discover:</p> <ul> <li>What advanced testing captures that conventional strategies often miss</li> <li>How to identify which cardiac implantable electronic devices (CIED s) require advanced testing and when standard testing will suffice</li> <li>The steps to build a chemical characterization strategy that survives PMA review, toxicology risk assessment (TRA), and later design iterations</li> <li>How integrating lab and regulatory strategy early in development reduces rework and de-risks approvals</li> </ul><br><br><a href="http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_rqma01">Request Free!</a></td></tr></table> http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_veew18 http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_veew18 Mon, 29 Jun 2026 18:20:08 -0700 <table><tr><td valign=top><a href="http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_veew18"><img src="http://img.tradepub.com/free/w_veew18/images/w_veew18c.gif" border=0></a></td><td valign=top><p>Recent data shows that 34% of U.S. biopharma launches fail to meet their first-year forecasts. The primary culprit? A staggering 64% of industry leaders admit they lack the commercial data foundation required for success. In an increasingly competitive market, &quot;good enough&quot; data is no longer an option.</p> <p><strong>In February 2026, Veeva surveyed 125 senior commercial operations, analytics, marketing, and data strategy professionals to uncover the structural gaps separating successful launches from the rest.</strong></p> <p>Download the report to discover:</p> <ul> <li><strong>Top Launch Pitfalls:</strong> Identify the data challenges currently stalling brand momentum.</li> <li><strong>The AI Readiness Gap:</strong> Why AI investments fail without accurate, harmonized data.</li> <li><strong>Accelerating Field Insights:</strong> How to turn fragmented data into actionable intelligence for your sales teams.</li> </ul><br><br><a href="http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_veew18">Request Free!</a></td></tr></table> http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_catd22 http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_catd22 Mon, 29 Jun 2026 18:10:09 -0700 <table><tr><td valign=top><a href="http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_catd22"><img src="http://img.tradepub.com/free/w_catd22/images/w_catd22c.gif" border=0></a></td><td valign=top><p>Pierre Fabre collaborated with Catalent to develop the first oral vinorelbine softgel capsule for use in approved oncology indications. This formulation enabled oral delivery of a traditionally intravenous chemotherapy agent, representing a meaningful advancement in patient-centered drug administration.</p> <p>The softgel form achieved consistent systemic exposure and has been approved in multiple European markets. Catalent supported formulation development, clinicalphase as well as commercial manufacturing.</p> <p>This oral dosage form also played a pivotal role in life cycle management: first launched in 2001, the oral formulation provided a differentiated follow-on to the intravenous product, helping to sustain brand value and market share in the face of intravenous generic competition that emerged in 2007.</p><br><br><a href="http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_catd22">Request Free!</a></td></tr></table> http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_catd23 http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_catd23 Mon, 29 Jun 2026 18:01:34 -0700 <table><tr><td valign=top><a href="http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_catd23"><img src="http://img.tradepub.com/free/w_catd23/images/w_catd23c.gif" border=0></a></td><td valign=top><p>As clinical trials grow increasingly decentralised and patient-centric, traditional clinical supply chains often fall short. This shift is driven by the increasing complexity of therapies, the need for faster market entry, and a focus on sustainability. This executive summary evaluates clinical supply models and introduces FastChain&reg;, Catalent&rsquo;s demand-led decentralized model that aligns supply with real-time patient needs. With scalable, on-demand clinical supply solutions, sponsors can reduce drug overage and waste and accelerate study start-up across global regions. Specialized case management combined with demand-led clinical supply, are ideal for temperature-sensitive and high value investigational therapies.</p> <p>Learn more about:</p> <ul> <li>How demand-led supply models reduce overage and support rapid country activation.</li> <li>Combining flexible supply strategies with specialist case management to increase speed, flexibility, and global patient access for complex clinical programs.</li> <li>Real‑world case studies where sponsors used FastChain&reg; demand-led supply for measurable cost, speed, and efficiency impact.</li> </ul><br><br><a href="http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_catd23">Request Free!</a></td></tr></table> http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_visb06 http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_visb06 Mon, 29 Jun 2026 18:01:24 -0700 <table><tr><td valign=top><a href="http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_visb06"><img src="http://img.tradepub.com/free/w_visb06/images/w_visb06c.gif" border=0></a></td><td valign=top><p>Supply chains are under more pressure than ever to balance resilience, efficiency, and growth&mdash;while navigating disruption, rising expectations, and increasing complexity. As AI becomes a critical driver of productivity and performance, organizations are discovering that success depends on more than adding intelligent capabilities. It starts with the right foundation.</p> <p>In this IDC report, explore how leading organizations are using AI to improve visibility, accelerate decision-making, strengthen agility, and unlock measurable supply chain outcomes. Learn why cloud-based platforms are emerging as the backbone for scalable AI adoption&mdash;and why companies investing in modern supply chain technology are better positioned to adapt and compete.</p> <p>Common misconceptions about cloud ERP&mdash;including concerns around cost, usability, and implementation timelines&mdash;continue to influence technology decisions. In reality, modern SAP Cloud ERP solutions are designed to simplify adoption and accelerate time to value, making advanced capabilities more attainable for organizations of all sizes.</p> <p>As a trusted, award-winning SAP partner, Vision33 helps organizations move beyond ERP misconceptions and build a connected digital core that powers AI-driven supply chain performance. Discover how the right cloud ERP strategy can accelerate time to value and create a stronger foundation for long-term operational success.</p><br><br><a href="http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_visb06">Request Free!</a></td></tr></table> http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_visb05 http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_visb05 Mon, 29 Jun 2026 18:01:16 -0700 <table><tr><td valign=top><a href="http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_visb05"><img src="http://img.tradepub.com/free/w_visb05/images/w_visb05c.gif" border=0></a></td><td valign=top><p>Supply chains are under increasing pressure to become more agile in the face of ongoing disruption. Organizations need more than incremental improvements&mdash;they need intelligent technologies that connect data, improve visibility, and enable faster, confident decision-making.</p> <p>In this guide, discover how AI is helping organizations transform supply chain operations through embedded intelligence across planning, manufacturing, logistics, and asset management. Learn how AI can improve forecasting accuracy, streamline operations, increase collaboration across teams, and help organizations anticipate and respond to change in real time.</p> <p>While many organizations recognize the need to modernize, adoption is often slowed by long-standing myths surrounding cloud ERP&mdash;such as concerns around complexity or disruption. In reality, cloud ERP can increase agility, improve visibility across operations, and create a connected digital foundation that supports smarter decisions and stronger supply chain performance.</p> <p>As a multi-award-winning SAP partner, Vision33 helps organizations accelerate digital transformation with practical strategies and deep SAP expertise. Explore how Vision33 can help you unlock the value of AI and cloud ERP to build a smarter, more connected supply chain.</p><br><br><a href="http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_visb05">Request Free!</a></td></tr></table> http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_visb04 http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_visb04 Mon, 29 Jun 2026 18:01:08 -0700 <table><tr><td valign=top><a href="http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_visb04"><img src="http://img.tradepub.com/free/w_visb04/images/w_visb04c.gif" border=0></a></td><td valign=top><p>Supply chain leaders are navigating growing complexity. Yet many organizations remain constrained by legacy systems, and disconnected data, limiting their ability to respond with speed and confidence.</p> <p>This IDC Analyst Brief explores how modern, AI-powered cloud ERP is helping organizations build more resilient, agile, and connected supply chains. By unifying applications, data, and AI on a single platform, businesses can improve visibility, accelerate decision-making, increase productivity, and adapt more effectively to change.</p> <p>Common misconceptions around cloud ERP&mdash;including cost, complexity, and implementation timelines&mdash;continue to delay modernization efforts. Modern SAP Cloud ERP solutions are helping dispel these myths by providing a more scalable, accessible, and faster path to value while creating the foundation needed to support AI-driven supply chain performance.</p> <p>Discover key IDC insights on evolving supply chain priorities and the growing role of AI in operational performance.</p> <p>As a global, award-winning SAP partner, Vision33 helps organizations turn these insights into action&mdash;supporting businesses in adopting scalable cloud ERP solutions that create a stronger foundation for growth, innovation, and supply chain performance.</p><br><br><a href="http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_visb04">Request Free!</a></td></tr></table> http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_squd38 http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_squd38 Mon, 29 Jun 2026 17:40:20 -0700 <table><tr><td valign=top><a href="http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_squd38"><img src="http://img.tradepub.com/free/w_squd38/images/w_squd38c.gif" border=0></a></td><td valign=top><p>In today&rsquo;s highly competitive food and beverage landscape, lasting concepts are rarely accidental. They are shaped by a clear point of view, disciplined execution, and the ability to evolve without losing what made them resonate in the first place.</p> <p>This article follows artist and entrepreneur Kelis as she spends time with the teams behind Miss Lily&rsquo;s, Harlem Hops, and Van Leeuwen&mdash;exploring how each has navigated the realities of building, refining, and sustaining a concept over time.</p> <p>Don&rsquo;t miss this valuable look at the decisions, trade-offs, and creative discipline required to turn a restaurant concept into something that continues to resonate and perform.</p><br><br><a href="http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_squd38">Request Free!</a></td></tr></table> http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_splu663 http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_splu663 Mon, 29 Jun 2026 17:20:08 -0700 <table><tr><td valign=top><a href="http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_splu663"><img src="http://img.tradepub.com/free/w_splu663/images/w_splu663c.gif" border=0></a></td><td valign=top><p>Public sector leaders are under pressure to deliver reliable, secure, and transparent services despite limited resources and increasing digital complexity. This book serves as a practical guide to achieving digital resilience, featuring twenty real-world examples of how organizations are leveraging Splunk to unify security, observability, and automation. By exploring these proven, scalable strategies&mdash;structured by challenge, vertical, and measurable outcomes&mdash;readers will gain the insights needed to detect issues early, respond faster, and maintain public trust in an ever-evolving digital landscape.</p> <p>In this ebook you will find:</p> <ul> <li><strong>Real-World Use Cases</strong>:&nbsp;Explore 20 distinct applications, including real-time situational awareness for emergency services, cyber defense, fraud detection, and predictive maintenance for critical infrastructure.</li> <li><strong>Proven Outcomes</strong>:&nbsp;Learn how organizations like the Bank of England, Cal Poly, and Imperial College London are using Splunk to achieve measurable results&mdash;from faster incident response to millions in cost savings.</li> <li><strong>Actionable Intelligence</strong>:&nbsp;Understand how to unify security, observability, and automation to build a more resilient, transparent, and efficient public sector.</li> </ul> <p>To save you time, every use case is tagged by&nbsp;<strong>Challenge</strong>&nbsp;and&nbsp;<strong>Vertical</strong>, so you can find what works for your specific mission in seconds.</p> <p>Download the guide, pick one use case that fits your current headache, and see if you can't clear a bit of space in your week.</p><br><br><a href="http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_splu663">Request Free!</a></td></tr></table> http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_lenb97 http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_lenb97 Mon, 29 Jun 2026 16:40:09 -0700 <table><tr><td valign=top><a href="http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_lenb97"><img src="http://img.tradepub.com/free/w_lenb97/images/w_lenb97c.gif" border=0></a></td><td valign=top><p>Through the combined strengths of Intel&rsquo;s high-performance silicon, Red Hat&rsquo;s enterprise-grade software, and Lenovo&rsquo;s ruggedized hardware, businesses can modernize edge infrastructure with built-in AI acceleration, confidential computing, and scalable open source platforms, enabling secure, real-time value from AI-driven edge operations.</p> <p>Download this White Paper to learn how&nbsp;the three-way partnership between Intel, Red Hat, and Lenovo can result in a&nbsp;scalable, secure approach that transforms edge AI from isolated experiments into a strategic advantage for digital transformation.</p><br><br><a href="http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_lenb97">Request Free!</a></td></tr></table> http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_dasa660 http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_dasa660 Mon, 29 Jun 2026 16:20:17 -0700 <table><tr><td valign=top><a href="http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_dasa660"><img src="http://img.tradepub.com/free/w_dasa660/images/w_dasa660c.gif" border=0></a></td><td valign=top><p>Companies running Virtual Twins on the <strong>3D</strong>EXPERIENCE platform are seeing results that reshape what's possible in heavy mobile machinery:</p> <p>~50% quicker time to market<br /> ~25% better product quality<br /> ~10% increased revenues</p> <p>This isn't a distant promise. By 2028, the machinery market will exceed $5 trillion, and 75% of businesses in advanced sectors have already adopted Virtual Twins.</p> <p><strong>See the Full Picture</strong></p> <p>Our infographic maps how Total Quality Management (TQM) &nbsp;and the Virtual Twin Experience are transforming the industry, from the moment a product is conceived to when it leaves the market. You'll see how the <strong>3D</strong>EXPERIENCE platform connects people, ideas and data across the full product lifecycle, builds quality into every stage and supports a culture of continuous improvement.</p> <p>It's a fast, visual read for engineering leaders who want the proof points at a glance. Get the data-driven story behind smarter, faster and higher-quality machinery development.</p><br><br><a href="http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_dasa660">Request Free!</a></td></tr></table> http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_dasa659 http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_dasa659 Mon, 29 Jun 2026 16:20:08 -0700 <table><tr><td valign=top><a href="http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_dasa659"><img src="http://img.tradepub.com/free/w_dasa659/images/w_dasa659c.gif" border=0></a></td><td valign=top><p>In mobile heavy equipment, reactive quality management costs you time, money, and competitive ground. The <strong>3D</strong>EXPERIENCE platform and Virtual Twins give you the tools to build quality into every stage of development, from design to post-sales.</p> <p>What you'll learn:</p> <ul> <li>Reduce product development costs by up to 49%</li> <li>Replace siloed, manual processes with model-based, data-driven quality management</li> <li>Gain full visibility across your supply chain and product lifecycle</li> </ul> <p>Download <em>Transforming Quality Management in Heavy Machinery with Virtual Twins</em> and see how leading manufacturers are making the shift.</p><br><br><a href="http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_dasa659">Request Free!</a></td></tr></table> http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_biod34 http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_biod34 Mon, 29 Jun 2026 15:51:54 -0700 <table><tr><td valign=top><a href="http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_biod34"><img src="http://img.tradepub.com/free/w_biod34/images/w_biod34c.gif" border=0></a></td><td valign=top><p>Confocal microscopy gives scientists sharp, clear images of cells and intracellular structures, letting them study cellular organization, dynamics, and functions in 3D and over time. Today&rsquo;s confocal microscopes are integrated systems that offer enhanced resolution, spectral flexibility, and automation. As such, choosing an appropriate microscope platform for a given project can be daunting.<br /> <br /> Download this guide to&nbsp;learn more about what confocal microscopes can do &mdash; from 3D imaging to live-cell imaging and more &mdash; and how to choose the right system for a given application.</p><br><br><a href="http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_biod34">Request Free!</a></td></tr></table> http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_hrcs42 http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_hrcs42 Mon, 29 Jun 2026 14:40:57 -0700 <table><tr><td valign=top><a href="http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_hrcs42"><img src="http://img.tradepub.com/free/w_hrcs42/images/w_hrcs42c.gif" border=0></a></td><td valign=top><p>BLS task-based analysis projects that 62% of US jobs will require significant redesign by 2032 &mdash; but 2026 is the year the wave hits hardest as AI adoption accelerates from pilot to enterprise-wide, economic uncertainty forces faster workforce decisions, and demographic shifts tighten talent pools simultaneously. This preview identifies the single force driving redesign in 2026, profiles the five occupations experiencing the fastest transformation &mdash; from customer service to production workers &mdash; with before and after skill comparisons, and provides a state-level risk and opportunity index covering California, Texas, Florida, New York, and Michigan. A practical three-move preparation checklist gives HR leaders and executives immediate actions to audit role automation risk, launch AI augmentation pilots, and begin critical upskilling conversations before the redesign wave arrives. Written by Tresha Moreland &mdash; MBA, SPHR, FACHE &mdash; founder of HR C-Suite and independent workforce strategy researcher whose work is syndicated through LexisNexis, ProQuest, and Refinitiv.</p><br><br><a href="http://pinoybizblogger.tradepub.com/c/pubRD.mpl?sr=rss&_t=rss&qf=w_hrcs42">Request Free!</a></td></tr></table>